Mechanisms of Antidepressant Non-Response in Late-Life Depression

• Status: Completed
• Trial end date: 2020-01-17
• Target enrollment: 0
• Participant gender: All

Summary

This project seeks to elucidate the mechanisms by which antidepressant medications have limited efficacy in Late Life Depression (LLD) in order to develop new treatment interventions for this prevalent and disabling illness. Investigators hypothesize that the presence of executive dysfunction (ED),which is common in depressed adults over 60, impairs the ability to form appropriate expectancies of improvement with antidepressant treatment. Greater expectancy has been shown to improve antidepressant treatment outcome and is hypothesized to be a primary mechanism of placebo effects. Moreover, white matter hyperintensities (WMH) on magnetic resonance imaging (MRI) are more prevalent in patients with LLD compared to healthy controls. It has been argued that WMH contribute to the pathogenesis of LLD with ED and decrease the efficacy of antidepressant medications by disrupting connections between prefrontal cortical (PFC) and subcortical structures. Vascular lesions to white matter tracts may also compromise the pathway by which expectancy-based placebo effects influence depressive symptoms. Expectancies reflect activation in PFC areas that may improve depressive symptoms by modulating the activity of subcortical regions subserving negative affective systems (i.e., amygdala) as well as those important in reward and hedonic capacity (nucleus accumbens and ventral striatum). Thus, LLD patients with ED and WMH may sustain a "double-hit" to their ability to experience placebo effects in antidepressant treatments: ED diminishes the ability to generate appropriate treatment expectancies, while WMH disrupt the physiologic pathways by which expectancies lead to improvement in depressive symptoms.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Treatments: Antidepressive Agents; Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Men and women aged 60-90 years

• Diagnosis with nonpsychotic Diagnostic and Statistical Manual (DSM) IV MDD

• 24-item Hamilton Rating Scale for Depression (HRSD) score ≥ 16

• Willing to and capable of providing informed consent and complying with study procedures

Exclusion Criteria:

• Current comorbid Axis I DSM IV disorder other than Nicotine Dependence, Adjustment Disorder, or Anxiety Disorder

• diagnosis of substance abuse or dependence (excluding Nicotine Dependence) within the past 12 months

• History of psychosis, psychotic disorder, mania, or bipolar disorder

• Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease

• MMSE < 24

• HRSD suicide item > 2 or Clinical Global Impressions (CGI)-Severity score of 7 at baseline

• history of allergic or adverse reaction to escitalopram, or non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) during the current episode

• current treatment with psychotherapy, antidepressants, antipsychotics, or mood stabilizers

• having contraindication to MRI scanning (such as metal in body) or unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)

• acute, severe, or unstable medical or neurological illness